Using PSMA-PET to guide melanoma surgery planning
Official title: Preoperative Planning With PSMA-PET in Melanoma Surgery Trial
Run by Royal Marsden NHS Foundation Trust · NCT06560905 · Data updated 2026-11-12
We will see if a PSMA PET/CT scan can find melanoma spread more clearly than the standard FDG PET/CT in adults with palpable lymph nodes or limited metastatic melanoma who are scheduled for surgery.
Quick facts
| Phase | Phase 2 |
|---|---|
| Study type | Interventional |
| Ages | 18 Years and up |
| Sex | Men only |
| Enrollment | 16 (estimated) |
| Sponsor | Royal Marsden NHS Foundation Trust Academic / other |
| Locations | 1 site (London) |
| Status | Recruiting |
| Started | March 11, 2025 |
| Main results expected | December 31, 2025 |
| Study ends | December 31, 2025 |
| Registry record updated | July 1, 2025 |
| Trial ID | NCT06560905 on ClinicalTrials.gov |
Is this trial a fit for you?
✓Likely a good fit
Adult men (≥18) with biopsy-proven primary or recurrent metastatic melanoma who have palpable lymph node disease or limited metastases, have had an FDG PET/CT, and are scheduled for surgical resection are ideal candidates.
✕Probably not a fit
Women, patients with widespread metastatic disease, those with prior prostate cancer or on androgen-deprivation therapies, or patients unable to undergo PET/CT are unlikely to benefit from this PSMA-PET approach.
A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.
What this trial studies
This is a non-randomised, single-centre Phase 2 imaging study comparing 68Ga-PSMA PET/CT with the standard FDG PET/CT in patients with palpable nodal disease or oligometastatic melanoma. Participants (male adults) will undergo PSMA PET/CT in addition to their routine FDG PET/CT, with imaging findings compared to intraoperative findings and pathology where available. The trial aims to determine whether PSMA imaging can improve 3D lymphatic mapping and better delineate nodal disease in complex anatomical areas. Improved lesion detection could inform more precise surgical planning and potentially reduce the extent of dissection and operative morbidity.
Why it matters
Potential benefit: If successful, PSMA-PET could improve detection of melanoma metastases and enable more precise surgical planning that reduces the extent of dissection and related morbidity.
How similar studies have gone: PSMA-PET is well established in prostate cancer but its application to melanoma is novel with only limited preliminary reports and no large-scale validation to date.
Who can join: the full rules
Show full inclusion / exclusion criteria
Inclusion Criteria: * Males ≥18 years of age * Biopsy proven first and recurrent metastatic melanoma with palpable nodal disease who have undergone a staging FDG PET-CT scan as part of routine clinical care and are scheduled for surgery for resection of the primary site Exclusion Criteria: * Patients unable to give voluntary written informed consent to participate in this study * Patients not willing to complete all the study assessments * Patients who are females * Patients who are taking androgen deprivation therapy (ADT) and other therapies targeting the androgen pathway, such as androgen receptor antagonists. * Patients who have or have previously been diagnosed with prostate cancer * Patients who have had Lu-177 PSMA therapy or barium studies within a period of 10 days prior to undergoing PSMA PET-CT scanning * Patients not fluent in English
Where it's running
-
The Royal Marsden NHS Foundation Trust
London, United Kingdom Recruiting
Study contacts
- Principal investigator: Myles Smith — Royal Marsden NHS Foundation Trust
- Study coordinator: Reyhaneh Sadegh Zadeh
- Email: reyhaneh.sadeghzadeh@rmh.nhs.uk
- Phone: 020 7352 8171
Similar studies
Other studies for the same condition or treatment. Recruiting studies are listed first.
-
Social prescriptions and micro-learning to improve cancer care
This study tests a multicomponent program using social prescriptions and short online learning to help cancer patients and their chosen support persons in Germany.
-
TCC1727 combined with other cancer medicines for adults with advanced solid tumors
This phase Ib/II trial tests TCC1727 given with benmelstobart, olaparib, or topotecan in adults with advanced solid tumors to find safe doses and see if the combinations help control tumors.
-
Regular supervised exercise to reduce symptoms in melanoma
This trial tests whether a 12-week supervised exercise program can reduce fatigue and improve quality of life for adults with stage IIb–IV melanoma who are receiving immunotherapy or targeted therapy.
-
Video consultations for cancer treatment recommendations
This study is testing if video consultations can help patients with malignant melanoma get better treatment recommendations by connecting them with cancer experts from different specialties, no matter where they live.
-
Testing a new antibody treatment for advanced solid tumors and liver cancer
This study is testing a new antibody treatment for people with advanced solid tumors and liver cancer to see if it is safe and how well it works.
-
Evaluating LB-LR1109 for treating solid tumors
This study is testing a new treatment called LB-LR1109 to see how safe it is and how well it works for people with advanced solid tumors that can't be treated with standard options.
How to take part
- Review the eligibility criteria above with your treating physician.
- Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
- Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.